Cargando…
An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma
We evaluated the usefulness of an oncolytic virus (Suratadenoturev; OBP-301) against radioresistant oral squamous cell carcinoma. We confirmed the expression of human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor in cell lines. Also, we examined the potential presen...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619351/ https://www.ncbi.nlm.nih.gov/pubmed/36381653 http://dx.doi.org/10.1016/j.omto.2022.10.001 |
_version_ | 1784821256164474880 |
---|---|
author | Gohara, Shunsuke Shinohara, Kosuke Yoshida, Ryoji Kariya, Ryusho Tazawa, Hiroshi Hashimoto, Masashi Inoue, Junki Kubo, Ryuta Nakashima, Hikaru Arita, Hidetaka Kawaguchi, Sho Yamana, Keisuke Nagao, Yuka Iwamoto, Asuka Sakata, Junki Matsuoka, Yuichiro Takeshita, Hisashi Hirayama, Masatoshi Kawahara, Kenta Nagata, Masashi Hirosue, Akiyuki Kuwahara, Yoshikazu Fukumoto, Manabu Okada, Seiji Urata, Yasuo Fujiwara, Toshiyoshi Nakayama, Hideki |
author_facet | Gohara, Shunsuke Shinohara, Kosuke Yoshida, Ryoji Kariya, Ryusho Tazawa, Hiroshi Hashimoto, Masashi Inoue, Junki Kubo, Ryuta Nakashima, Hikaru Arita, Hidetaka Kawaguchi, Sho Yamana, Keisuke Nagao, Yuka Iwamoto, Asuka Sakata, Junki Matsuoka, Yuichiro Takeshita, Hisashi Hirayama, Masatoshi Kawahara, Kenta Nagata, Masashi Hirosue, Akiyuki Kuwahara, Yoshikazu Fukumoto, Manabu Okada, Seiji Urata, Yasuo Fujiwara, Toshiyoshi Nakayama, Hideki |
author_sort | Gohara, Shunsuke |
collection | PubMed |
description | We evaluated the usefulness of an oncolytic virus (Suratadenoturev; OBP-301) against radioresistant oral squamous cell carcinoma. We confirmed the expression of human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor in cell lines. Also, we examined the potential presence in a patient who has received existing therapy that is amenable to treatment with OBP-301. We evaluated: (1) the antitumor effects of OBP-301 alone and in combination with radiotherapy on radioresistant cell lines, (2) the molecular mechanism underlying the radiosensitizing effect and cell death increased by the combination therapy, and (3) the antitumor effect of the combination therapy in vivo using xenograft models (a radioresistant cell line-derived xenograft in mouse and a patient-derived xenograft). Human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor were expressed in all cell lines. OBP-301 decreased the proliferative activity of these cell lines in a concentration-dependent manner, and significantly enhanced the antitumor effect of irradiation. Phosphorylated STAT3 and its downstream molecules, which correlated with apoptosis and autophagy, showed significant changes in expression after treatment with OBP-301. The combination therapy exerted a significant antitumor effect versus radiotherapy alone in both xenograft models. Combination of OBP-301 with radiotherapy exerts a synergistic effect and may represent a promising treatment for radioresistant oral squamous cell carcinoma. |
format | Online Article Text |
id | pubmed-9619351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-96193512022-11-14 An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma Gohara, Shunsuke Shinohara, Kosuke Yoshida, Ryoji Kariya, Ryusho Tazawa, Hiroshi Hashimoto, Masashi Inoue, Junki Kubo, Ryuta Nakashima, Hikaru Arita, Hidetaka Kawaguchi, Sho Yamana, Keisuke Nagao, Yuka Iwamoto, Asuka Sakata, Junki Matsuoka, Yuichiro Takeshita, Hisashi Hirayama, Masatoshi Kawahara, Kenta Nagata, Masashi Hirosue, Akiyuki Kuwahara, Yoshikazu Fukumoto, Manabu Okada, Seiji Urata, Yasuo Fujiwara, Toshiyoshi Nakayama, Hideki Mol Ther Oncolytics Original Article We evaluated the usefulness of an oncolytic virus (Suratadenoturev; OBP-301) against radioresistant oral squamous cell carcinoma. We confirmed the expression of human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor in cell lines. Also, we examined the potential presence in a patient who has received existing therapy that is amenable to treatment with OBP-301. We evaluated: (1) the antitumor effects of OBP-301 alone and in combination with radiotherapy on radioresistant cell lines, (2) the molecular mechanism underlying the radiosensitizing effect and cell death increased by the combination therapy, and (3) the antitumor effect of the combination therapy in vivo using xenograft models (a radioresistant cell line-derived xenograft in mouse and a patient-derived xenograft). Human telomerase reverse transcriptase and the coxsackievirus and adenovirus receptor were expressed in all cell lines. OBP-301 decreased the proliferative activity of these cell lines in a concentration-dependent manner, and significantly enhanced the antitumor effect of irradiation. Phosphorylated STAT3 and its downstream molecules, which correlated with apoptosis and autophagy, showed significant changes in expression after treatment with OBP-301. The combination therapy exerted a significant antitumor effect versus radiotherapy alone in both xenograft models. Combination of OBP-301 with radiotherapy exerts a synergistic effect and may represent a promising treatment for radioresistant oral squamous cell carcinoma. American Society of Gene & Cell Therapy 2022-10-08 /pmc/articles/PMC9619351/ /pubmed/36381653 http://dx.doi.org/10.1016/j.omto.2022.10.001 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Gohara, Shunsuke Shinohara, Kosuke Yoshida, Ryoji Kariya, Ryusho Tazawa, Hiroshi Hashimoto, Masashi Inoue, Junki Kubo, Ryuta Nakashima, Hikaru Arita, Hidetaka Kawaguchi, Sho Yamana, Keisuke Nagao, Yuka Iwamoto, Asuka Sakata, Junki Matsuoka, Yuichiro Takeshita, Hisashi Hirayama, Masatoshi Kawahara, Kenta Nagata, Masashi Hirosue, Akiyuki Kuwahara, Yoshikazu Fukumoto, Manabu Okada, Seiji Urata, Yasuo Fujiwara, Toshiyoshi Nakayama, Hideki An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma |
title | An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma |
title_full | An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma |
title_fullStr | An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma |
title_full_unstemmed | An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma |
title_short | An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma |
title_sort | oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619351/ https://www.ncbi.nlm.nih.gov/pubmed/36381653 http://dx.doi.org/10.1016/j.omto.2022.10.001 |
work_keys_str_mv | AT goharashunsuke anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT shinoharakosuke anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT yoshidaryoji anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kariyaryusho anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT tazawahiroshi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT hashimotomasashi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT inouejunki anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kuboryuta anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT nakashimahikaru anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT aritahidetaka anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kawaguchisho anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT yamanakeisuke anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT nagaoyuka anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT iwamotoasuka anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT sakatajunki anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT matsuokayuichiro anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT takeshitahisashi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT hirayamamasatoshi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kawaharakenta anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT nagatamasashi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT hirosueakiyuki anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kuwaharayoshikazu anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT fukumotomanabu anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT okadaseiji anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT uratayasuo anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT fujiwaratoshiyoshi anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT nakayamahideki anoncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT goharashunsuke oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT shinoharakosuke oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT yoshidaryoji oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kariyaryusho oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT tazawahiroshi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT hashimotomasashi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT inouejunki oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kuboryuta oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT nakashimahikaru oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT aritahidetaka oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kawaguchisho oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT yamanakeisuke oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT nagaoyuka oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT iwamotoasuka oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT sakatajunki oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT matsuokayuichiro oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT takeshitahisashi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT hirayamamasatoshi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kawaharakenta oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT nagatamasashi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT hirosueakiyuki oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT kuwaharayoshikazu oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT fukumotomanabu oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT okadaseiji oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT uratayasuo oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT fujiwaratoshiyoshi oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma AT nakayamahideki oncolyticvirusasapromisingcandidateforthetreatmentofradioresistantoralsquamouscellcarcinoma |